These are all early tau phosphorylation sites (Wesseling et al., 2020), with pT217-tau and pT181-tau emerging as important fluid biomarkers of AD (Barthelemy et al., 2023; Horie et al., 2023; Janelidze et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.